The stock of Alnylam Pharmaceuticals Inc (ALNY) has gone up by 5.37% for the week, with a 1.68% rise in the past month and a 4.40% rise in the past quarter. The volatility ratio for the week is 4.49%, and the volatility levels for the past 30 days are 3.91% for ALNY. The simple moving average for the past 20 days is 3.88% for ALNY’s stock, with a 1.17% simple moving average for the past 200 days.
Is It Worth Investing in Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Right Now?
The 36-month beta value for ALNY is at 0.34. Analysts have varying views on the stock, with 11 analysts rating it as a “buy,” 11 rating it as “overweight,” 9 as “hold,” and 1 as “sell.”
The public float for ALNY is 124.35M, and currently, shorts hold a 2.00% of that float. The average trading volume for ALNY on March 20, 2025 was 692.92K shares.
ALNY) stock’s latest price update
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY)’s stock price has gone rise by 0.51 in comparison to its previous close of 253.44, however, the company has experienced a 5.37% increase in its stock price over the last five trading days. zacks.com reported 2025-03-14 that ALNY stock soars 62% in a year, driven by increasing Amvuttra and Givlaari sales. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
Analysts’ Opinion of ALNY
Goldman gave a rating of “Buy” to ALNY, setting the target price at $370 in the report published on August 16th of the previous year.
ALNY Trading at -0.39% from the 50-Day Moving Average
After a stumble in the market that brought ALNY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.32% of loss for the given period.
Volatility was left at 3.91%, however, over the last 30 days, the volatility rate increased by 4.49%, as shares surge +3.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.37% upper at present.
During the last 5 trading sessions, ALNY rose by +7.40%, which changed the moving average for the period of 200-days by +74.93% in comparison to the 20-day moving average, which settled at $245.45. In addition, Alnylam Pharmaceuticals Inc saw 8.25% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALNY starting from Fitzgerald Kevin Joseph, who sale 1,911 shares at the price of $243.73 back on Mar 03 ’25. After this action, Fitzgerald Kevin Joseph now owns 14,345 shares of Alnylam Pharmaceuticals Inc, valued at $465,772 using the latest closing price.
Fitzgerald Kevin Joseph, the CSO & EVP, Head of Research of Alnylam Pharmaceuticals Inc, sale 844 shares at $241.15 during a trade that took place back on Mar 04 ’25, which means that Fitzgerald Kevin Joseph is holding 13,501 shares at $203,532 based on the most recent closing price.
Stock Fundamentals for ALNY
Current profitability levels for the company are sitting at:
- -0.08 for the present operating margin
- 0.86 for the gross margin
The net margin for Alnylam Pharmaceuticals Inc stands at -0.12. The total capital return value is set at -0.06.
Based on Alnylam Pharmaceuticals Inc (ALNY), the company’s capital structure generated 0.95 points at debt to capital in total, while cash flow to debt ratio is standing at -0.01. The debt to equity ratio resting at 19.32. The interest coverage ratio of the stock is -1.25.
Currently, EBITDA for the company is -178.85 million with net debt to EBITDA at -1.71. When we switch over and look at the enterprise to sales, we see a ratio of 14.84. The receivables turnover for the company is 5.55for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.78.
Conclusion
In conclusion, Alnylam Pharmaceuticals Inc (ALNY) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
